MAPS: Who We Are

Executive
- Rick Doblin, Ph.D., Founder and Executive Director
- Merete Christiansen, Executive Manager and Assistant to Rick Doblin, Ph.D.

Clinical Research
- Ali Lilienstein, M.D., M.P.H., Clinical Research Associate - Physician
- Berra Yazargil-Klosinski, Ph.D., Associate Director of Clinical Research

Communications and Marketing
- Brian Brown, Communications and Marketing Manager
- Brad Burge, Director of Strategic Communications
- Sarah Jordan, Publications Associate
- Cara LaChance, Social Media Communications and Marketing Associate
- Amy Mastrine, Web and Email Marketing Associate
- Bryce Montgomery, Associate Director of Communications and Marketing

Development
- Erik Brown, Development Manager
- Tess Shelley, Development Specialist
- Jade Netanya Ullmann, Development Officer and Connector
- Ryan Beauregard, Zendo Project Manager
- Sara Gael, M.A., Director of Harm Reduction, Zendo Project

Harm Reduction (Zendo Project)

Operations
- Aidan Boling, Operations Associate
- Kynthia Brunette, Information Systems Specialist
- Jenni Vierra, Sales and Outreach Associate

Policy and Advocacy
- Ismail L. Ali, JD, Policy & Advocacy Counsel
- Natalie Lyta Ginsberg, Policy & Advocacy Director
The MAPS Public Benefit Corporation (MPBC) is a wholly owned subsidiary of MAPS. The special purpose of MPBC is to balance income from the legal sale of MDMA with the social benefits of MAPS’ mission by serving as a vehicle for conducting MAPS’ psychedelic and marijuana research initiatives.

MPBC’s primary work is completing Phase 2 studies of MDMA-assisted psychotherapy for PTSD, and preparing for the Phase 3 clinical trials required to develop MDMA-assisted psychotherapy into an approved treatment for PTSD. MAPS continues to conduct education and harm reduction projects, to raise funds for MPBC projects, and serve as parent organization and sole funder of MPBC. MPBC was incorporated on December 19, 2014.

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

MAPS further its mission by:

- Developing psychedelics and marijuana into prescription medicines.
- Training therapists and working to establish a network of treatment centers.
- Supporting scientific research into spirituality, creativity, and neuroscience.
- Educating the public honestly about the risks and benefits of psychedelics and marijuana.

MAPS envisions a world where psychedelics and marijuana are safely and legally available for beneficial uses, and where research is governed by rigorous scientific evaluation of their risks and benefits.

MAPS relies on the generosity of individual donors to achieve our mission. Now that research into the beneficial potential of psychedelics is again being conducted under federal guidelines, the challenge has become one of funding. No funding is currently available for this research from pharmaceutical companies or major foundations. That means that the future of psychedelic and marijuana research is in the hands of individual donors. Please consider making a donation today.

maps.org/donate